Sagent (SGNT) Launches Flumazenil Injection
Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) announced the launch of Flumazenil Injection, USP, a benzodiazepine antagonist, in two latex-free vial presentations. According to IMS for the 12 months ending September 2012, the US market for Flumazenil Injection, USP approximated $5.6 million. As with all products in Sagent's portfolio, Flumazenil features the Company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.
You May Also Be Interested In
- Needham & Company Downgrades Sagent Pharmaceuticals (SGNT) to Hold
- Orexigen Therapeutics (OREX) Receives Day 180 List from CHMP for NB32
- Durata Therapeutics (DRTX) Unit Enters Licensing Agreement with Angelini
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!